{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:14:06Z","timestamp":1793506446824,"version":"4.5.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"the Zhongguancun Foundation"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lecanemab reduces amyloid levels and modestly slows cognitive decline in a large cohort of early Alzheimer's disease (AD) but lacks real-world safety data in Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The real-world study aims to analyze baseline characteristics and preliminary safety of lecanemab for AD in Zhejiang Province, and to evaluate the efficacy of plasma biomarkers for patient screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-center study included 190 patients with AD in Zhejiang Province, who completed baseline assessments and received lecanemab treatment with follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 176 participants with early AD and 14 moderate. In the early AD (mean age 68.04 years, Mini-Mental State Examination 20.03 and Montreal Cognitive Assessment 14.93), 124 (70.5%) participants were female, and 127 (72.1%) were junior high school education level or less.\n                      <jats:italic toggle=\"yes\">APOE4<\/jats:italic>\n                      heterozygote was predominant (48.9%). Logistic regression for distinguishing early AD from the A\u03b2 negative cognitively unimpaired populations showed that p-Tau 217 independently provided better classification efficacy (area under the curve\u2009=\u20090.9983, p\u2009&lt;\u20090.0001). In the early AD, 29 (16.5%) participants experienced infusion-related reactions (IRR) after the first-dose lecanemab, and amyloid-related imaging abnormalities (ARIA) were identified in 17 patients (9.7%), while 3 (21.4%) with IRR and none ARIA observed in the moderate AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The real-world lecanemab cohort had more females, lower educational level, and higher disease burden compared with the clinical trial cohort. Overall lecanemab exhibited a manageable short-term safety profile with no measurable cognitive efficacy. Extensive monitoring and management are required for ARIA of clinically importance. The plasma p-Tau 217 showed high accuracy for early AD screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251406619","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:39:43Z","timestamp":1765809583000},"page":"1346-1356","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3771-5135","authenticated-orcid":false,"given":"Lumin","family":"Leng","sequence":"first","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengluan","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Zhejiang Provincial People's Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Ningbo University, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinv","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Neurology, the Ningbo No.2 Hospital, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengya","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huzhou Central Hospital, the Affiliated Central Hospital of Huzhou University, Huzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiye","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, the First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. Dementia https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia (2025)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30185-7"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000344650.95823.03"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100195"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200303000-00004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29215131"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24494"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240171"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13770"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad057"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02275-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.10.967"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.149.2.351"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8469"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_3_21_2","unstructured":"Food and Drug Administration. Lecanemab https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761178s011lbl.pdf (2024)."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.12779\/dnd.2024.23.4.165"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01640-3"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2579"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00700-w"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.159"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207156"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308719"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2024.2438188"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9220"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26411"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251406619","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:51Z","timestamp":1777370991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251406619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/13872877251406619"],"URL":"https:\/\/doi.org\/10.1177\/13872877251406619","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}